AbbVie's upadacitinib nabs accelerated review status in U.S. for atopic dermatitis

|About: AbbVie Inc. (ABBV)|By:, SA News Editor

The FDA designates AbbVie's (ABBV -2.4%) JAK1 inhibitor upadacitinib a Breakthrough Therapy for treatment of atopic dermatitis. A Phase 3 study should launch by Q2.

Breakthrough Therapy status provides for more intensive guidance from the FDA on development, the involvement of more senior agency personnel and a rolling review of the marketing application.

Previously: FDA tags Novartis and Shire candidates Breakthrough Therapies (Jan. 4)

Subscribe for full text news in your inbox